Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus.

O'Malley, Tyler; Xie, Fenglong; Su, Yujie; Clinton, Cassie; Zack, Debra J; Haechung, Chung; Grabner, Michael; Curtis, Jeffrey R

O'Malley, Tyler; Xie, Fenglong; Su, Yujie; Clinton, Cassie; Zack, Debra J; Haechung, Chung; Grabner, Michael; Curtis, Jeffrey R.

Afiliação

O'Malley T; Exagen Inc., Vista, CA.
Xie F; Division of Clinical Immunology and Rheumatology, School of Medicine, University of Alabama at Birmingham.
Su Y; Division of Clinical Immunology and Rheumatology, School of Medicine, University of Alabama at Birmingham.
Clinton C; Division of Clinical Immunology and Rheumatology, School of Medicine, University of Alabama at Birmingham.
Zack DJ; Exagen Inc., Vista, CA.
Haechung C; HealthCore, Inc., Wilmington, DE.
Grabner M; HealthCore, Inc., Wilmington, DE.
Curtis JR; Division of Clinical Immunology and Rheumatology, Department of Medicine and Department of Epidemiology, School of Medicine, University of Alabama at Birmingham.

J Manag Care Spec Pharm ; 28(9): 1021-1032, 2022 Sep.

Article em En | MEDLINE | ID: mdl-35775579

Assuntos

Lúpus Eritematoso Sistêmico; Medicare; Idoso; Ativação do Complemento; Humanos; Lúpus Eritematoso Sistêmico/diagnóstico; Lúpus Eritematoso Sistêmico/tratamento farmacológico; Estudos Retrospectivos; Resultado do Tratamento; Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Medicare / Lúpus Eritematoso Sistêmico Tipo de estudo: Diagnostic_studies / Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans País como assunto: America do norte Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google